Earnings Releases·Nov 13, 2026, 12:12 PM ET

Integrated BioPharma — Q3 2026 Earnings Summary

Revenue declined 22% year-over-year to $9.9 million from $12.7 million, driven by high customer concentration where the top two clients accounted for 88% of total revenue.
Financial results deteriorated significantly with gross profit turning negative to $(112) thousand (vs. $1.019 million in 2025), resulting in an operating loss of $(961) thousand and a net loss of $(691) thousand.
Operating expenses remained relatively stable with selling and administrative costs at $849 thousand, down slightly from $856 thousand in the prior year period.
Management acknowledged the revenue decline and customer concentration risks, while the company continues operations in the manufacturing and distribution of vitamins and nutritional supplements.
No specific guidance changes, M&A activity, or capital return announcements were included in the provided summary.